New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
07:34 EDTARIAARIAD long-term risk/reward ratio compelling, says RBC Capital
RBC Capital believes that several upcoming events could enable ARIAD's stock to advance significantly more than bears expect. Such events include stronger than expected sales of the company's Iclusig drug and positive clinical results for its '113 lung cancer drug. The firm keeps a $28 price target and Outperform rating on the shares.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
10:53 EDTARIAOptions with increasing implied volatility
Options with increasing implied volatility: THRX ALTR ARIA DECK ANF KORS CVC CCE
09:26 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTARIAARIAD enters into settlement agreement with Sarissa Capital Management
Subscribe for More Information
07:02 EDTARIAARIAD says Harvey Berger to retire as chairman and CEO
Subscribe for More Information
06:22 EDTARIAARIAD settles with Sarissa Capital, CEO to retire by end of year
Subscribe for More Information
April 22, 2015
07:38 EDTARIAARIAD issued U.S. patent on brigatinib
Subscribe for More Information
April 21, 2015
14:30 EDTARIAARIAD could be worth double current value to strategic buyer, BBJ BioFlash says
Subscribe for More Information
07:36 EDTARIAARIAD anounces results of preclinical studies on Brigatinib at AACR meeting
ARIAD Pharmaceuticals announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor, brigatinib at the American Association for Cancer Research Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer, who are resistant to crizotinib. An oral presentation describes, for the first time, the design and chemical structure of brigatinib, discovered using ARIADís structure-based drug design platform. With the goal of designing a selective ALK inhibitor with broad-based activity against crizotinib-resistant mutants, ARIAD scientists advanced a series of novel compounds culminating in the identification of brigatinib. Brigatinib incorporates unique chemical-design features, including the distinctive use of a recognition element that confers favorable pharmacologic properties. Brigatinib has at least 10-fold greater potency than crizotinib against ALK+ NSCLC cell lines and was broadly active against clinically relevant crizotinib-resistant mutants in preclinical models. A poster presentation shows that brigatinib, at clinically achievable concentrations, has potent anti-tumor activity against a panel of 17 distinct ALK mutants known to confer resistance to other ALK inhibitors. In a separate study designed to model the occurrence of brain metastases in ALK+ lung cancer patients, brigatinib significantly reduced the tumor burden in mice with ALK+ brain tumors compared to the tumors in mice treated with crizotinib. Survival of brigatinib-treated mice was also markedly enhanced compared to the survival duration of crizotinib-treated mice.
April 20, 2015
07:20 EDTARIAAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use